Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014.

Author: BryantP A, ChangC C, ChenS C, PaigeE K, SlavinM A, SorrellT C

Paper Details 
Original Abstract of the Article :
Pathogenic yeast forms are commonly associated with invasive fungal disease in the immunocompromised host, including patients with haematological malignancies and patients of haemopoietic stem cell transplants. Yeasts include the Candida spp., Cryptococcus spp., Pneumocystis jirovecii and some lesse...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1111/imj.12597

データ提供:米国国立医学図書館(NLM)

Fighting Yeast Infections: A Guide for Immunocompromised Patients

Invasive fungal infections pose a significant threat to immunocompromised patients, particularly those undergoing hematological and oncologic treatments. This research provides evidence-based guidelines for the antifungal management of established yeast infections in these vulnerable populations. The guidelines address the most common causes of invasive yeast infections, including Candida species, Cryptococcus species, and Pneumocystis jirovecii, and offer practical recommendations for treatment and prevention.

Navigating Antifungal Therapy: A Comprehensive Approach

The guidelines offer a comprehensive framework for antifungal therapy, covering both established and potential yeast infections. They provide specific recommendations for managing different types of yeast infections, considering factors such as patient characteristics, infection severity, and drug resistance. The guidelines emphasize the importance of early diagnosis and prompt treatment to improve patient outcomes.

Protecting Immunocompromised Patients

This research provides invaluable guidance for healthcare professionals treating immunocompromised patients. It offers a practical and evidence-based framework for managing yeast infections, ensuring appropriate and timely treatment. It's like finding a well-stocked oasis in the desert of fungal infections, providing essential tools and resources for protecting vulnerable patients.

Dr.Camel's Conclusion

Fungal infections can pose a significant challenge to immunocompromised patients. This research provides crucial guidelines for managing these infections, ensuring effective and timely treatment. It's like finding a safe haven in the desert of fungal infections, offering a comprehensive approach to protecting vulnerable patients.

Date :
  1. Date Completed 2015-08-25
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

25482743

DOI: Digital Object Identifier

10.1111/imj.12597

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.